Lattice Biologics is recruiting 10 patients for it Phase 1 clinical trial in Seattle to assess its novel stem cell therapy, AmnioBoost, for the treatment of COVID-19 lung disease.
BELGRADE, Mont. — Lattice Biologics Ltd. has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection. AmnioBoost is derived from amniotic fluid taken from non-related, healthy, living donors during a Caesarian delivery. The baby is not harmed in any way. [Read more…]